Table 2.
Clinical characteristics of patients with moderate COVID-19 on admission
| Characteristics | Training set (n = 70) | Validation set (n = 31) | ||||
|---|---|---|---|---|---|---|
| All patients (n = 70) | Liver function damage group (n = 45) | Normal liver function group (n = 25) | All patients (n = 31) | Liver function damage group (n = 21) | Normal liver function group (n = 10) | |
| Sex n (%) | ||||||
| Male | 34 (48.6) | 22 (48.9) | 12 (48.0) | 14 (45.2) | 8 (38.1) | 6 (60.0) |
| Female | 36 (51.4) | 23 (51.1) | 13 (52.0) | 17 (54.8) | 13 (61.9) | 4 (40.0) |
| Age (years) /M (IQR) | 52.81 ± 15.92 | 54.11 ± 15.77 | 50.48 ± 16.24 | 52.06 ± 18.52 | 56.14 ± 18.41 | 43.50 ± 16.44 |
| Any comorbidities n (%) | ||||||
| Cardiovascular disease | 18 (25.7) | 14 (31.1) | 4 (16.0) | 5 (16.1) | 4 (19.1) | 1 (10.0) |
| Endocrine system disease | 8 (11.4) | 4 (8.9) | 4 (16.0) | 4 (12.9) | 4 (19.1) | - |
| Others | 11 (15.7) | 9 (20.0) | 2 (8.0) | 5 (16.1) | 4 (19.1) | 1 (10.0) |
| Chief complaint n (%) | ||||||
| Cough | 34 (48.6) | 27 (60.0)* | 7 (28.0) | 20 (64.5) | 14 (66.7) | 6 (60.0) |
| Fever | 21 (30.0) | 15 (33.3) | 6 (24.0) | 11 (35.5) | 10 (47.6) | 1 (10.0) |
| Fatigue | 9 (12.7) | 6 (13.3) | 3 (12.0) | 7 (22.6) | 4 (19.1) | 3 (30.0) |
| Others | 11 (15.7) | 8 (17.8) | 3 (12.0) | 10 (32.3) | 7 (33.3) | 3 (30.0) |
| Drug use n (%) | ||||||
| Traditional Chinese medicine | 59 (84.3) | 39 (86.7) | 20 (80.0) | 23 (74.2) | 17 (81.0) | 6 (60.0) |
| Antiviral drugs | 54 (77.1) | 32 (71.1) | 22 (88.0) | 19 (61.3) | 13 (61.9) | 6 (60.0) |
| Anti-inflammatory drugs | 12 (17.1) | 8 (17.8) | 4 (16.0) | 2 (6.5) | 2 (9.5) | – |
| Others | 16 (22.9) | 12 (26.7) | 4 (16.0) | 1 (3.2) | – | 1 (10.0) |
| Length of hospitalization (days) /M (IQR) | 19.69 ± 6.90 | 19.42 ± 7.60 | 20.16 ± 5.54 | 20.00 (16.00–24.00) | 20.00 (17.00–24.00) | 16.50 (11.75–21.25) |
COVID-19: coronavirus disease 2019. : Average. s: Standard deviation. M (IQR): Median (Quartile)
*Significant difference between the liver function damage group and the normal liver function group, P < 0.05